August Emerging Medical Technologies Report

•An approach to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications such as: central nervous system (CNS) disorders, cancer, inflammation & metabolic diseases, viral & bacterial infections, and orphan diseases
•The first self-contained disposable blood test to measure the level of proteins (disease biomarkers) from a single droplet of finger-pricked blood to diagnose, monitor, and manage a variety of medical conditions, including: heart failure, cancer, osteoporosis, critical pregnancy, and infectious diseases
•1-Closure device that utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant, which dissolves within 30 days, leaving nothing behind but a healed femoral artery and 2-A radial compression band that achieves quick and effective hemostasis, while protecting the ulnar nerve and providing a comfortable experience for the patient
•Breast cancer screening system with very high sensitivity (95% at 1 cm) that checks for abnormalities using three proven methods: advanced thermal profiling (ATP), optical spectroscopy, and ultrasound
•Significantly improved accuracy, sensitivity, and convenience in trace and sub-trace analyses using mass spectrometers and a patented technology platform, to aid in understanding some of the complex underlying factors that trigger or accelerate many diseases
•Accurate, wearable body monitoring systems for: diabetes management, sleep disorder treatment, weight loss, and elderly care assistance
•Small molecule caspase activators for the treatment of cancer and other proliferative diseases
•Compounds that leverage the therapeutic potential of Omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of: inflammatory bowel disease (IBD), severe hypertriglyceridemia & dyslipidemia, multiple sclerosis (MS), chronic kidney disease (CKD), psoriasis, and an ultra-orphan metabolic disease
•Regional cerebral thermal therapy (RCTT) device to treat insomnia and sleep disorders
•1-Large and small molecules designed to amplify the body's innate ability to efficiently burn fuels like glucose and 2-Next-generation highly selective insulin sensitizers
•A therapeutic vaccine with companion diagnostic and monitoring tool, to improve celiac disease management
•Device for treating chronic obstructive pulmonary disease (COPD), without leaving any implant behind in the patients' lung tissue
•Portable oxygen concentrator that makes its own oxygen from surrounding air, thus, never running out of oxygen
•Robots that allow doctors to actually see and respond to patients in ICUs and emergency rooms remotely, giving physicians the ability to perform routine duties, such as patient rounds, via a web interface
•Next-generation, hand-held, low-powered ultrasound brush that delivers proprietary anti-aging ingredients to reduce wrinkles
•Small molecule drugs that will provide well-tolerated therapies for cancer, preneoplastic conditions, and other diseases of pathologic proliferation, including inflammation and viral diseases
•1-The first heart pacemaker that recruits stem cells to damaged heart tissue and converts them to muscle and 2-Electrical stimulation device to treat wounds secondary to peripheral limb ischemia, foot ulcers, and other slow healing wounds
•High-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases such as: Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease, Alzheimer's disease (AD), and multiple sclerosis (MS), as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease
•Completely portable systems that provide high-quality computed tomography (CT) images wherever needed, including: the clinic, Intensive Care Unit (ICU), Operating Room (OR), and Emergency Room (ER)/Trauma Department
•Compounds to treat pain, epilepsy, and other nervous system disorders such as: anxiety, autism, migraine, schizophrenia, and bipolar
•An improved and more predictable bioavailability, as compared to currently available Omega-3 products, for the treatment of lipid disorders (dyslipidemia) and hypertriglyceridemia
•Entirely new class of naturally occurring human supercharged proteins that function inside of cells, to address a broad spectrum of previously undruggable targets, with potential applications for inflammatory, infectious, and ophthalmic diseases
•NSAID formulations, which have the potential to reduce the serious and common gastrointestinal (GI) side-effects caused by virtually all existing NSAIDs
•Small-peptide therapeutics for metabolic diseases such as: obesity, diabetes, and gastrointestinal (GI) functional disorders like diabetic gastroparesis (DG)
•Simple blood tests to predict the risks of preterm birth, preeclampsia, and other pregnancy complications
•Non-surgical office-based treatments that addresses common bladder disorders such as: stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction, and lower urinary tract symptoms (LUTS)
•The first women's bra that recruits stem cells to breast tissue, for enlargement without surgery. Cells are recruited via an electrical homing signal from the woman's own fat tissue and bone marrow
•Ready-to-use pharmaceuticals, delivered through patient-friendly injection devices, that will eliminate reconstitution, simplify administration, and ease the pain of injections